Healthcare / Drug Manufacturers - Specialty & GenericBSE
$124.00
+2.30 (+1.89%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-15.4M · quality 46.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
41.5x
↑EV/EBITDA
11.7x
↓ROE
4.7%
↑Gross Margin
55.5%
↑Debt/Equity
0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
-10.2%
FCF CAGR
+73.5%
FCF margin
13.5%
FCF / Net income
4.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.02B · net income $34.3M · FCF $137.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.02B | $1.02B | $1.26B | $1.27B | $1.41B |
| Net Income | $34.3M | $34.3M | $35.6M | $35.9M | $41.3M |
| EBITDA | $127.0M | $127.0M | $122.7M | $113.3M | $94.4M |
| EPS | — | — | 3.11 | 3.14 | 3.61 |
| Gross Margin | 55.5% | 55.5% | 45.6% | 41.0% | 33.3% |
| Operating Margin | 6.6% | 6.6% | 5.3% | 5.2% | 3.7% |
| Net Margin | 3.4% | 3.4% | 2.8% | 2.8% | 2.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.11 | 0.11 | 0.24 | 0.17 | 0.08 |
| Current Ratio | 1.98 | 1.98 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $137.9M | $137.9M | $-15.4M | $-38.4M | $26.4M |
| Returns | |||||
| ROE | 4.7% | 4.7% | 5.0% | 5.2% | 6.1% |
| Valuation | |||||
| P/E | 41.47 | 41.47 | 36.48 | — | — |
| EV/EBITDA | 11.70 | 11.70 | 11.94 | — | — |
| P/B | 1.93 | 1.93 | 1.81 | — | — |
| Growth & Yield | |||||
| Revenue Growth | -19.1% | -19.1% | -0.7% | -9.8% | — |
| EPS Growth | — | — | -1.0% | -13.0% | — |
| Dividend Yield | 1.2% | 1.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-8.3%
Start / end P/E
n/dx → n/dx
EPS bridge
3.11 → n/d
Residual
-9.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.